5087-21-8

Usage

Uses

Used in Pharmaceutical Industry:
(1R,2R)-2-(4-methoxyphenyl)cyclopropanecarboxylic acid is used as a key intermediate in the synthesis of various pharmaceutical compounds for its unique structural properties and potential to modulate biological activities. Its chiral nature allows for the development of enantiomer-specific drugs, which can exhibit different pharmacological effects and reduce potential side effects.
Used in Agrochemical Industry:
In the agrochemical sector, (1R,2R)-2-(4-methoxyphenyl)cyclopropanecarboxylic acid is utilized as a building block for the creation of novel agrochemicals with enhanced efficacy and selectivity. Its cyclopropane ring and 4-methoxyphenyl group may contribute to the development of new pesticides or herbicides with improved target specificity and reduced environmental impact.
Further research is necessary to fully explore the potential applications and effects of (1R,2R)-2-(4-methoxyphenyl)cyclopropanecarboxylic acid in various fields, including but not limited to, pharmaceuticals and agrochemicals.

Upstream product

• 623-73-4 diazoacetic acid ethyl ester 
• 637-69-4 4-Methoxystyrene 
• 943-89-5 (E)-3-(4-methoxyphenyl)acrylic acid 
• 3901-07-3 3-(4-methoxy-phenyl)acrylic acid methyl ester 
• 948551-64-2 methyl trans-2-(4-methoxyphenyl)cyclopropanecarboxylate 

Downstream Products

• 1314323-99-3 (1R,2S)-2-(4-methoxyphenyl)cyclopropanamine hydrochloride 
• 1314323-95-9 (1R,2S)-tert-butyl 2-(4-methoxyphenyl)cyclopropylcarbamate 
• 220349-83-7 (1R,2S)-2-(4-methoxyphenyl)cyclopropanamine 

Relevant academic research and scientific papers

KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE

Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDMIA, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.

Enantioselective synthesis of tranylcypromine analogues as lysine demethylase (LSD1) inhibitors

Asymmetric cyclopropanation of styrenes by tert-butyl diazoacetate followed by ester hydrolysis and Curtius rearrangement gave a series of tranylcypromine analogues as single enantiomers. The o,- m- and p-bromo analogues were all more active than tranylcypromine in a LSD1 enzyme assay. The m- and p-bromo analogues were micromolar growth inhibitors of the LNCaP prostate cancer cell line as were the corresponding biphenyl analogues prepared from the bromide by Suzuki crosscoupling.

Triazolo(4,5-d)pyrimidine compounds

Triazolo[4,5-d]pyrimidine compounds are provided of the formula (I) wherein R1, R2, R3, R4, R5and R6are as defined in the specification. Compositions containing the compounds are also provided, together with processes for their preparation and methods of use in the treatment of diseases, including myocardial infarction and unstable angina.

New prolyl endopeptidase inhibitors: In vitro and in vivo activities of azabicyclo[2.2.2]octane, azabicyclo[2.2.1]heptane, and perhydroindole derivatives

A series of potent and selective prolylendopeptidase (PEP) inhibitors of the α-keto heterocyclic type has been obtained by replacing the classical central proline of 1-[1-(4-phenylbutanoyl)-L-prolyl]pyrrolidine (SUAM 1221, 3) by non-natural amino acids PHI, ABO, and ABH. These 4-phenylbutanoyl side- chain-containing inhibitors exhibited potent in vitro inhibitory potencies with IC50 around 30 nM (compounds 24 and 25). Modulation of the side chain by replacement of the terminal phenyl ring by the dicyclopropyl moiety afforded derivatives 30 and 32 with improved potencies (IC50 between 10 and 20 nM). Furthermore, replacing the linear 4-phenylbutanoyl side chain by the (2-phenylcyclopropyl)carbonyl entity provided potent inhibitors with IC50 culminating at 0.9 nM on a rat cortex enzymatic preparation (compound 70). The configuration of the cyclopropyl ring had to be R,R in order to obtain not only a strong PEP inhibition in vitro but also a good activity in vivo, exemplified by inhibitor 68, which gave ID50 ip and po of 0.3 and 1 mg/kg, respectively. Finally, demonstration of the cognition-enhancing properties of compound 54 was given in the passive avoidance test using scopolamine- induced amnesia in the rat, where it dose dependently inhibited the scopolamine-induced decrease in avoidance response.